Jaramillo Segura, S., Krisam, J., Le Cornet, L., Kratzmann, M., Baumann, L., Eissymont, O., . . . Schlenk, R. F. (2024). Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia: Letters to the editor. Haematologica, 109(6), . https://doi.org/10.3324/haematol.2023.284346
Chicago-Zitierstil (17. Ausg.)Jaramillo Segura, Sonia, et al. "Randomized Phase III GnG Study on Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and Double-blinded Intensive Postremission Therapy with or Without Glasdegib in Patients with Newly Diagnosed Acute Myeloid Leukemia: Letters to the Editor." Haematologica 109, no. 6 (2024). https://doi.org/10.3324/haematol.2023.284346.
MLA-Zitierstil (9. Ausg.)Jaramillo Segura, Sonia, et al. "Randomized Phase III GnG Study on Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and Double-blinded Intensive Postremission Therapy with or Without Glasdegib in Patients with Newly Diagnosed Acute Myeloid Leukemia: Letters to the Editor." Haematologica, vol. 109, no. 6, 2024, https://doi.org/10.3324/haematol.2023.284346.